Closing the Stable Door After the Horse Has Bolted: Should We Be Treating People With Immune-Tolerant Chronic Hepatitis B to Prevent Hepatocellular Carcinoma?
- 1 June 2020
- journal article
- editorial
- Published by Elsevier BV in Gastroenterology
- Vol. 158 (8), 2028-2032
- https://doi.org/10.1053/j.gastro.2020.02.027
Abstract
No abstract availableFunding Information
- Bristol-Myers Squibb
- AbbVie
- Gilead Sciences
This publication has 29 references indexed in Scilit:
- Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNAGastroenterology, 2014
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyThe Lancet, 2013
- Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infectionJournal of Hepatology, 2012
- Minimization of hepatitis B infection by a 25-year universal vaccination programJournal of Hepatology, 2012
- Preserved T-Cell Function in Children and Young Adults With Immune-Tolerant Chronic Hepatitis BGastroenterology, 2012
- Long-term Therapy With Tenofovir Is Effective for Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis B VirusGastroenterology, 2010
- Nomograms for Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus InfectionJournal of Clinical Oncology, 2010
- Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factorsJournal of Hepatology, 2008
- Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral LoadGastroenterology, 2006
- Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA LevelJAMA, 2006